Companies /Healthcare

Coherus Biosciences Inc

NASDAQ: CHRS Biotechnology
$0.39
▼ $0.02 (−5.56%) today
Markets closed · 4:46pm ET

CHRS at a Glance

Valuation
Market cap
$69.5M
Profitability
Revenue (TTM)
$53.6M
Profit margin
-253.4%
EPS (TTM)
$-1.12
Price
52-week range
$0 – $3
Street target
$7.25

Headquartered in Redwood City, CA Fiscal year ends December NASDAQ: CHRS coherus.com

About Coherus Oncology

Coherus Oncology (Nasdaq: CHRS) is a commercial-stage oncology company. It sells LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor and the only FDA-approved and available U.S. treatment for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC). LOQTORZI is the NCCN's only preferred Category 1 first-line option with cisplatin and gemcitabine and its only preferred subsequent-line treatment.

The company exited its biosimilar business in 2025. Its strategy now rests on two pillars:
- growing LOQTORZI sales in NPC;
- developing two mid-stage antibody immunotherapy candidates in combination with LOQTORZI.

The two candidates are:
- tagmokitug, a selective cytolytic anti-CCR8 antibody that depletes tumor regulatory T cells, now prioritized for esophageal cancer (ESCC and EAC) and also being studied in prostate cancer with pasritamig;
- casdozokitug, an IL-27 antagonist in a Phase 2 study in first-line hepatocellular carcinoma.

Coherus holds global rights to both candidates and plans ex-U.S. licensing deals as clinical data support them. In November 2026 it announced a restructuring that cuts headcount by about 30% to lower cash burn. Updated

CHRS Coverage

Frequently Asked Questions

What does Coherus Oncology do?

Coherus Oncology (Nasdaq: CHRS) is a commercial-stage oncology company. It sells LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor and the only FDA-approved and available U.S. treatment for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC).

What is the CHRS stock price target?

The Wall Street consensus 12-month price target for CHRS is $7.25.